GlassScriptPhysician profile
Rotimi Royce Ayoola
NPI 1639519523
$7,627.21
in general payments reported to CMS, 2019-2025
30 companies · $2,029 in 2025
The $2,029 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $777 · 2020: $192 · 2021: $214 · 2022: $878 · 2023: $1,637 · 2024: $1,899 · 2025: $2,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,543 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,542.61 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,269.07 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,135.33 | 2021-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $489.07 | 2024-2025 | Voquezna |
| Genzyme Corporation | $420.42 | 2022-2025 | |
| Janssen Biotech, INC. | $415.71 | 2022-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $407.24 | 2021-2025 | Entyvio, Eohilia |
| Regeneron Healthcare Solutions, INC. | $368.72 | 2023-2025 | Dupixent |
| Gilead Sciences, INC. | $318.49 | 2022-2025 | |
| Ardelyx, INC. | $295.92 | 2022-2025 | Ibsrela |
| Pfizer INC. | $275.33 | 2019-2025 | |
| Celgene Corporation | $212.18 | 2022-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $154.69 | 2022-2023 | |
| Boston Scientific Corporation | $101.76 | 2020-2025 | Cre Pro, General - Metal Stents - G.I. |
| Ironwood Pharmaceuticals, INC | $91.98 | 2023-2024 | Linzess |
| Aimmune Therapeutics, INC. | $78.02 | 2024-2025 | Zenpep |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $75.20 | 2022-2023 | Dificid |
| Ipsen Biopharmaceuticals, INC | $73.66 | 2024-2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $73.34 | 2024-2025 | |
| Qol Medical, LLC | $58.69 | 2022-2025 | Sucraid |
| Lilly USA, LLC | $58.16 | 2024-2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $42.55 | 2022-2023 | Rebyota |
| Alnylam Pharmaceuticals INC. | $33.49 | 2025 | Givlaari |
| Evoke Pharma, INC. | $28.88 | 2024-2025 | |
| Madrigal Pharmaceuticals | $27.02 | 2025 | Rezdiffra |
| Sandoz INC. | $26.62 | 2023 | Hyrimoz |
| Novo Nordisk INC | $22.69 | 2025 | Wegovy |
| Redhill Biopharma INC. | $21.54 | 2024 | Talicia |
| Medtronic, INC. | $19.09 | 2025 | Synchromedii |
| Alexion Pharmaceuticals, INC. | $16.63 | 2022 | |
| Albireo Pharma, INC. | $15.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rotimi Ayoola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.